



Curriculum Vitae

Personal information C. Susana Rojo

Work experience

1. Employer: Spanish Medicines Agency
 - Start date: January 2009
 - End date:
 - Position: Quality Assessor
 - Activities: Quality Assessor
 - Country: Spain
2. Employer: Centro de Biología Molecular Severo Ochoa
 - Start date: July 2000
 - End date: May 2007
 - Position: Postdoctoral Contract
 - Activities: Research in Immunology
 - Country: Spain
3. Employer: INSERM, Institute de génétique et de biologie moléculaire et cellulaire (IGBMC) Illkirch (France)
 - Start date: October 1998
 - End date: March 2000
 - Position: Postdoctoral Contract
 - Activities: Research in Immunology
 - Country: France
4. Employer: National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda
 - Start date: January 1993
 - End date: June 1998
 - Position: Postdoctoral (visiting fellow and visiting associate)
 - Activities: Research in Immunology
 - Country: United States

Education and training

1. Subject: Universidad Complutense de Madrid
 - Start date:
 - End date: 1981
 - Qualification: Degree in Biology
 - Organisation:
 - Country: Spain
2. Subject: Universidad Complutense de Madrid
 - Start date:
 - End date: 1991
 - Qualification: PhD
 - Organisation: Immunology
 - Country: Spain
3. Subject: Fundación Jiménez Díaz, Madrid
 - Start date: January 1991
 - End date: December 1992
 - Qualification: Postdoctoral fellow
 - Organisation: Research in Immunology
 - Country: Spain

Additional information

Publications

- Physiological and biochemical properties and populations studies in the M Lactate Dehydrogenase polymorphism of *Discoglossus pictus* (Amphibia, Anura). Barja de Quiroga G, Rojo S, Gutierrez P, Alonso M. *Comp Biochem Physiol* 74B: 579-589. 1983. A comparative study of Superoxido Dismutase in amphibian tissues. Barja de Quiroga G, Gutierrez P, Rojo S, Alonso. *Comp Biochem Physiol* 77B: 589-596. 1984.
- Delineation of functional sites in HLA_B27 antigens. Molecular analysis of HLA_B27 variant Wewak I defined by cytolytic T lymphocytes. Vega MA, Wallace L, Rojo S, Bragado R, Aparicio P, López de Castro JA. *J. Immunol* 135: 3323-3332. 1985.
- Structural analysis of an HLA_B27 functional variant: Identification of residues that contribute to the specificity of recognition by cytolytic T lymphocytes. Vega MA, Ezquerro E, Rojo S, Aparicio P, Bragado R, López de Castro JA. *Proc Natl Acad Sci USA* 82: 7394-7398. 1985.
- HLA_B27 antigenicity: antibodies against the chemically synthesized 63_84 peptide from HLA_B27.1 display alloantigenic specificity and discriminate among HLA_B27 subtypes. Rojo S, López de Castro JA, Aparicio P, van Seventer G, Bragado R. *J Immunol* 137: 904-910. 1986.
- Structural analysis of an HLA_B27 population variant, B27f. Multiple patterns of amino acid changes within a single polypeptide segment generate polymorphism in HLA_B27. Rojo S, Aparicio P, Choo SY, Hansen JA, López de Castro JA. *J Immunol* 139: 831-836. 1987.
- Fine specificity of HLA_B27 cellular allorecognition. HLA_B27f is a functional variant distinguishable by cytolytic T cell clones. Aparicio P, Rojo S, Jaraquemada D, López de Castro JA. *J Immunol* 139: 837-841. 1987.
- Structural analysis of an HLA_B27 functional variant, B27d, detected in American Blacks. Rojo S, Aparicio

- P, Hansen JA, Choo SY, López de Castro JA. *J Immunol* 139: 3396_3401. 1987.
- Clonal heterogeneity of HLA_B27 allorecognition. Delineation of immunodominant sites. Aparicio P, Jaraquemada D, Rojo S, López de Castro JA. *Eur J Immunol* 18: 203_209. 1988.
 - Avidity dictates the lytic capacity of human cytolytic T lymphocyte clones with similar fine specificity against murine cells expressing B27 antigen. Calvo V, Rojo S, Aparicio P, Galocha B, López de Castro JA. *J Immunol* 141: 3798_3803. 1988.
 - Modulation on immunogenicity by HLA_B27 subtype polymorphism. Jaraquemada D, Galocha B, Aparicio P, Rojo S, Calvo V, López de Castro JA. *Eur. J. Immunol.* 18: 1945_1950. 1988.
 - Structure and Diversity of HLA_B27_specific T cell epitopes. Analysis with site_directed mutants mimicking HLA_B27 subtype polymorphism. Calvo V, Rojo S, López D, Galocha B, López de Castro JA. (A footnote in this paper specifies: "The contribution to this article by VC and SR is equal, and their order of authorship is arbitrary). *J Immunol.* 144: 4038_4045. 1990.
 - Conservation and Alteration of HLA_B27_specific T cell epitopes on mouse cells: implications for peptide_mediated alloreactivity. Rojo S, López D, Calvo V, López de Castro JA. *J Immunol.* 146: 634_642. 1991.
 - Peptide_presenting similarities among functionally distant HLA_B27 subtypes revealed by alloreactive T Lymphocytes of unusual specificity. López D, Rojo S, Calvo V, López de Castro JA. *J Immunol.* 148 : 996_1002. 1992.
 - Changes in the repertoire of peptides bound to HLA_B27 subtypes and to site_specific mutants inside and outside pocket B. Rojo S, García F, Villadangos JA, Lopez de Castro JA. *J Exp Med.* 177: 613_620. 1993.
 - Type I transmembrane receptor with inhibitory function in mouse mast cells and natural killer cells. Rojo S, Long EO, Wagtmann N. *J Immunol (Cutting Edge)* 158: 9_12. 1997.
 - Binding of a soluble p70 killer cell inhibitory receptor to HLA_B*5101: requirement for all three p70 immunoglobulin domains. Rojo S, Wagtmann N, Long EO. *Eur J Immunol* 27: 568_571. 1997.
 - T cell response to myelin basic protein in the context of the multiple sclerosis associated HLA_DR15 haplotype: peptide binding, immunodominance and effector functions of T cells. Vergelli M, Kalbus M, Rojo SC, Hemmer B, Kalbacher H, Tranquili L, Beck H, McFarland HF, De Mars R, Long EO, Martin R. *J Neuroimmunol* 77: 195_203. 1997.
 - A new human gene complex encodes the killer cell inhibitory receptors and a related family of monocyte/macrophage receptors. Wagtmann N, Rojo S, Eichler E, Mohrenweiser H and Long EO. *Curr Biol* 7:615_618. 1997.
 - Killer cell inhibitory receptors: diversity, specificity, and function. Long EO, Burshtyn DN, Clark WP, Peruzzi M, Ragatopalan S, Rojo S, Wagtmann N, Winter CC. *Immunological Reviews* 155: 135_144. 1997.
 - A high incidence of Shigella_induced arthritis in a primate specie: major histocompatibility complex class I molecules associated with resistance and susceptibility, and their relationship to HLA_B27. Urvater JA, McAdam SN, Loehrke JH, Allen TM, Moran JL, Rowell TJ, Rojo S, López de Castro JA, Taurog JD, and Watkins DI. *Immunogenetics* 51: 314_325. 2000.
 - Mast cells and natural killer cells from gp49B null mice are functional. Rojo S, Stebbins C, Peterson M, Dombrowicz D, Wagtmann N, and Long EO. *Mol. Cell. Biol.* 20: 7178_7182. 2000.
 - The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective. Laura Rodríguez, Pablo de Felipe, Raquel Martín, Jorge Martínez, David Ordóñez, Susana Rojo, Juan Fernando Martínez, Esther Rincón, Teresa Cejalvo, Irene Izquierdo, Inmaculada Montanuy, and Marcos Timón. *Hum Gene Ther.* 2025 Sep;36(17-18):1103-1117.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)